Results 201 to 210 of about 36,121,488 (330)

PICALM::MLLT10 translocated leukemia

FEBS Letters, EarlyView.
This comprehensive review of PICALM::MLLT10 translocated acute leukemia provides an in‐depth review of the structure and function of CALM, AF10, and the fusion oncoprotein (1). The multifaceted molecular mechanisms of oncogenesis, including nucleocytoplasmic shuttling (2), epigenetic modifications (3), and disruption of endocytosis (4), are then ...
John M. Cullen, Antonia C. Nakatsugawa, Natalie Barton, Henry Haines, Gary S. Stein, Janet L. Stein, Daniel S. Wechsler, Jessica L. Heath   +7 more
wiley   +1 more source

Anti-PLA2R antibody reduction as a predictor of treatment response in primary membranous nephropathy: a retrospective study. [PDF]

J Bras Nefrol
Bashir K, Asghar MR, Saleem N, Shahzil M, Riaz A, Hashmi MN, Sheraz A.   +6 more
europepmc   +1 more source

Cell wall target fragment discovery using a low‐cost, minimal fragment library

FEBS Letters, EarlyView.
LoCoFrag100 is a fragment library made up of 100 different compounds. Similarity between the fragments is minimized and 10 different fragments are mixed into a single cocktail, which is soaked to protein crystals. These crystals are analysed by X‐ray crystallography, revealing the binding modes of the bound fragment ligands.
Kaizhou Yan, Mathew Stanley, Olawale Raimi, Andrew T. Ferenbach, Helge C Dorfmueller, Daan M. F. van Aalten   +5 more
wiley   +1 more source

Cytokine Dynamics in Bortezomib-Induced Peripheral Neuropathy: Challenges in Translating Preclinical Findings to Humans. [PDF]

J Peripher Nerv Syst
Cebulla N, Schirmer D, Runau E, Flamm L, Terhorst C, Jähnel L, Güse J, Giordani N, Wieser A, Schoch F, Reinle ML, Gommersbach S, Papagianni A, Zhou X, Einsele H, Reinhold AK, Rittner H, Kortüm KM, Sommer C.   +18 more
europepmc   +1 more source

Intelligent nanoparticles for advanced drug delivery in cancer treatment

, 2015
David S. Spencer, Amey S. Puranik, Nicholas A. Peppas   +2 more
openalex   +2 more sources

AASLD guidelines for the treatment of hepatocellular carcinoma

Hepatology, 2018
J. Heimbach, L. Kulik, R. Finn, C. Sirlin, M. Abecassis, L. Roberts, A. Zhu, M. Murad, J. Marrero   +8 more
semanticscholar   +1 more source

Cell density–dependent nuclear‐cytoplasmic shuttling of SETDB1 integrates with Hippo signaling to regulate YAP1‐mediated transcription

FEBS Letters, EarlyView.
At low cell density, SETDB1 and YAP1 accumulate in the nucleus. As cell density increases, the Hippo pathway is gradually activated, and SETDB1 is associated with increased YAP1 phosphorylation. At high cell density, phosphorylated YAP1 is sequestered in the cytoplasm, while SETDB1 becomes polyubiquitinated and degraded by the ubiquitin–proteasome ...
Jaemin Eom, Jaewoong Jang, Jung Sun Park, Yong‐Kook Kang   +3 more
wiley   +1 more source

Study on nutritional status and incidence of sarcopenia in elderly patients with chronic heart failure. [PDF]

Asia Pac J Clin Nutr
Song S, Du H, Lu X, Luo B, Li Z.
europepmc   +1 more source

Treatment patterns and outcomes of unresectable pancreatic cancer patients in real-life practice: a region-wide analysis [PDF]

, 2018
Takeshi Terashima, Tatsuya Yamashita, Akito Sakai, Hajime Ohta, Yoshinobu Hinoue, Daisyu Toya, Hiroshi Kawai, Manabu Yonejima, Takeshi Urabe, Yatsugi Noda, Eishiro Mizukoshi, Shuichi Kaneko   +11 more
openalex   +1 more source

Inhibiting stearoyl‐CoA desaturase suppresses bone metastatic prostate cancer by modulating cellular stress, mTOR signaling, and DNA damage response

FEBS Letters, EarlyView.
Bone metastasis in prostate cancer (PCa) patients is a clinical hurdle due to the poor understanding of the supportive bone microenvironment. Here, we identify stearoyl‐CoA desaturase (SCD) as a tumor‐promoting enzyme and potential therapeutic target in bone metastatic PCa.
Alexis Wilson, Mackenzie K Herroon, Shane Mecca, Laimar C Garmo, Jacob Lindquist, Shrila Rajendran, Steve M. Patrick, Izabela Podgorski   +7 more
wiley   +1 more source